---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-020361"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:01:39.012382+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tonix licenses exclusive worldwide rights to TNX-4900 for neuropathic pain from Rutgers University

## Summary
- Licensed exclusive worldwide rights to TNX-4900 (S1R antagonist) from Rutgers University for chronic neuropathic pain.
- TNX-4900: Ki=7.5 nM, >100-fold selectivity over Sigma-2, oral bioavailability ~28%.
- Preclinical efficacy in diabetic and chemotherapy-induced neuropathic pain models without tolerance or motor impairment.
- Company plans IND-enabling studies; no financial terms disclosed.

## SEC filing metadata
- accession: 0001999371-25-020361
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125020361/0001999371-25-020361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125020361/tonix-8k_121625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-020361
- JSON: https://secwatch.observer/filing/0001999371-25-020361.json
- Plain text: https://secwatch.observer/filing/0001999371-25-020361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.